Honored to have received the 2024 Early Career Investigator Award from @OncJournal Thank you for selecting our study @susanebates @PasRescigno and @gbanna74 Nice interview at the link below 👇🏻
An interview with Dr. Francesco Schettini, winner of The Oncologist 2024 Early Career Investigator Award: academic.oup.com/oncolo/page… @susanebates @gbanna74 @PasRescigno
1
188
Francesco Schettini retweeted
🧬 Diez años de perfiles de expresión génica en cáncer de mama en Castilla y León: ¿qué hemos aprendido y qué nos queda por descubrir? Una década de experiencia clínica ha permitido avanzar en el uso de perfiles de expresión génica para orientar las decisiones terapéuticas en cáncer de mama. El XVIII Simposium dedicará una sesión a revisar los avances, los retos pendientes y las nuevas perspectivas en este campo. 🔬 La sesión contará con: ▪️ Dra. Isabel Gallegos (@isagalls), del Hospital General de Segovia, que abordará el panorama actual de los perfiles de expresión génica y sus retos futuros. ▪️ Dr. Francesco Schettini (@FraSchettMDPhD), del Hospital Clínic de Barcelona (@hospitalclinic), que compartirá los aprendizajes de la práctica clínica y del estudio OPTIMA. ▪️ Dr. Daniel Morchón (@dmorchon95), del Hospital Clínico Universitario de Valladolid, que repasará los diez años de experiencia en la realización de perfiles genómicos en cáncer de mama en Salamanca y Castilla y León. 🎙️ Modera: el Dr. César A. Rodríguez (@1969carodriguez), del Hospital Universitario de Salamanca – IBSAL (@IBSAL_IIS). 📅 6 de noviembre · 11:50–12:50 h · Salamanca 📄 Consulta el programa científico completo y descubre todas las sesiones del simposium. #SalamancaBases @1969carodriguez @Efonsecasanchez @rebecaLozMe @ciccancer @IBSAL_IIS @usal
3
4
219
Francesco Schettini retweeted
🔬 Our new review out in @EJCancer! Drugging the luminal axis in HR+/HER2− metastatic breast cancer: from next-gen ER therapies to PI3K/AKT/mTOR and CDK inhibition. 🙏 Special thanks to @CarmenCriscit and all co-authors! 🔗 doi.org/10.1016/j.ejca.2026.…
11
1
23
2,785
Aún con resaca de #ESMO2026, pero falta muy poco...os espero en Salamanca @usal el 6/11 para hablar de la implementación de #Prosigna en la práctica clínica real, revisar los resultado del OPTIMA y entender como cambiará esto las reglas del juego #SalamancaBases @1969carodriguez
1
2
155
A really enjoyable session today. Thanks to @c_sotiriou for the great moderation and the challenging questions! Thanks to the audience for being so engaging and thanks to all the friends and colleagues who took the time to come or watch the session! #ESMO2026
1
4
207
At 10.15 we will discuss about how lineage plasticity and mutational evolution in #breastcancer can guide treatment choices, with @c_sotiriou and those of you who would like to join
39
Francesco Schettini retweeted
One of the most awaited abstracts of #ESMO26: OS results of the NataLEE trial Adjuvant ribociclib provides statistically significant ⬆️ OS: delta of 1.2% at 60 months and 2.1% at 72 months (6-years) Confirmed and sustained benefit in IDFS, DDFS and DRFS @OncoAlert
5
14
31
1,285
It’s only been 2 days, and #ESMO2026 has been great so far! Most importantly, I couldn’t be prouder of my fellows, who have presented 3 posters and will deliver an oral presentation today! Shout-out to @giuspes @_callimaco @ACaltavituro 🙌🏻 for their hard work and dedication!
3
133
Francesco Schettini retweeted
At #ESMO26 rapid oral session on advanced #breastcancer @KalinskyKevin presents results from postMONARCH Abema + fulvestrant showed numeric, non significant ⬆️ OS in aBC after PD to CDK4-6i Modest PFS improvement @OncoAlert
1
7
11
688
We were very impressed yesterday 😂
POV: novel HER2 ADCs keep raising the bar in HER2-low breast cancer. @FraSchettMDPhD #ESMO26
1
4
352
Francesco Schettini retweeted
Good to have this option. Note approval only in mESR1.
Imlunestrant + Abema now @FDA ✅ based off EMBER-3: Ph III, #Imlunestrant +/-#Abemaciclib in HR+ mESR1 advanced BC! - Imlunestrant alone for mESR1 approved. - Combo⬆️ mPFS w/all comers (11.1mos vs 5.5mos) - If co-PIK3CA, Capi or this combo? #bcsm #OncTwitter @OncUpdates
2
5
1
39
3,195
Francesco Schettini retweeted
The Lancet staff are going on strike for the first time in the journal’s 200-year history. Is it surprising? I don’t think so. Authors produce the research and write the papers. Reviewers provide scientific evaluation, mostly for free. Editors carry much of the burden of keeping the system running. Then the same academic community pays thousands of dollars in APCs to make its own work open access. Yet staff are now striking over pay, while the publisher’s scientific, technical and medical division reports more than £1 billion in annual adjusted operating profit. So there is a simple question: where does all that money go? Authors, reviewers, editors, and institutions are carrying an ever-growing burden. I don’t think the current academic publishing model is sustainable. researchprofessionalnews.com…
20
216
27
514
63,677
Francesco Schettini retweeted
Datopotamab-DXd vs CT in previously treated inoperable/metastatic HR+ HER2- BC: safety & PROs from the ph3 TROPION Breast01 study in @ESMO_Open.Low grade nausea as most common TRAE. Dato-DXd delayed TTD in GHS/QoL, pain & physical functioning. esmoopen.com/action/showPdf?…
9
1
28
9,462
Proud to share our latest article! DYPD-guided dosing is useful to reduce toxicity also in metronomic capecitabine-based regimens. Check our study published in @JCOPO_ASCO in open access 👇🏻 @DanieleGeneral4 @giuspes @ACaltavituro @hospitalclinic
1
2
6
461
Francesco Schettini retweeted
The elacestrant/everolimus arm of ELEVATE out in @CCR_AACR (n=73). Recommended doses: ela 345 mg + eve 7.5 mg. Promising efficacy after CDK4/6i, with mPFS 8.3 mo, irrespective of ESR1/PIK3CA mutations. ADELA phase 3 trial ongoing to confirm these results. aacrjournals.org/clincancerr…
3
31
3
71
10,433
Francesco Schettini retweeted
Ovarian reserve predicts chemo benefit in RxPONDER (HR+/HER2-, node+, premenopausal <55): 🔹 AMH ≥10 pg/ml → CET cuts recurrence risk ~54% (HR 0.46) 🔹 AMH <10 pg/ml → no chemo benefit (HR 1.27) Estradiol/FSH/LH/progesterone: not predictive. @Larvol @OncoAlert
42
75
4,267
Francesco Schettini retweeted
I don't believe SERENA6 approval/rejection should open a debate about flexibility or innovation. This is about whether our ultimate goal is to treat patients or tumors. SERENA-6 is a great trial for tumors. Here 2 trial designs for patients - with @DrHBurstein and #MRegan
1
7
30
2,353
Francesco Schettini retweeted
It’s a bit of a long post👀 I wrote this letter on artificial intelligence and authorship nearly three years ago, when AI had not yet reached its current level. Today, my position is even clearer: we will get nowhere by rejecting AI. Just as computers, the internet, and statistical software became integral to scientific work, AI will become a natural part of academia. Those who ignore it will fall significantly behind those who use it effectively and may eventually face an existential professional challenge. But for me, one principle is non-negotiable: transparency. Some journals ask authors to declare that a manuscript was not written using AI. But does ticking a box really solve the ethical problem? If a journal effectively prohibits AI use, authors who use it will simply be more likely to conceal it. A system intended to protect transparency may therefore end up encouraging secrecy. We need to stop playing Pollyanna and confront the realities of scientific practice. AI use should be openly disclosed. New reporting categories should be developed according to the nature and extent of its contribution, and, where necessary, the principles of authorship responsibility and publication ethics should be redefined. The real ethical problem is not using AI. It is using AI and hiding it. Over the past three years, I have also had to confront a rather uncomfortable reality: in some areas, AI can think faster than I can, perform more comprehensive analyses, and write better manuscripts. As a result, I have found myself writing less. To be honest, this has brought a certain existential anxiety about the meaning of academic work. The issue is no longer simply that AI makes academics more efficient. It is beginning to perform some of the intellectual functions traditionally associated with academics—sometimes better than we do. In such an environment, it is unrealistic to expect researchers to continue producing with the same motivation, under the same publication pressures and performance metrics. Academia in the AI era cannot be governed merely through prohibitions and disclosure checkboxes. We need new systems of evaluation and incentive that motivate academics to formulate original questions, think critically, challenge assumptions, and take intellectual risks. The answer is not to resist AI. It is to redefine the human role in academia. esmoopen.com/article/S2059-7…
1
16
46
3,382